Antibody-Drug Conjugates May Represent the Future of HER2-Low Breast Cancer Treatment

Via Peters

Emerging data with novel antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan-nxki (Enhertu), vic-trastuzumab duocarmazine, and disitamab vedotin (Aidixi) are showing encouraging activity in HER2-low breast cancer. Paolo Tarantino, MD, said this data suggests that the classification of HER2 should go beyond merely positive or negative. “In the future, we will […]

Adjuvant Everolimus Fails to Stop Recurrence in Early High-Risk Breast Cancer

Via Peters

Adding mTOR inhibitor everolimus (Afinitor) to adjuvant endocrine therapy failed to improve disease-free survival (DFS) in high-risk hormone receptor-positive/HER2-negative (HR+/HER2-), a large randomized trial showed. Three-year DFS was 88% with everolimus plus endocrine therapy and 89% with placebo plus endocrine therapy. Tolerability figured prominently in the results, as more than […]

Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer

Via Peters

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia, Inc., a commercial-stage company focused on improving outcomes for breast cancer patients worldwide by providing physicians and patients with next-generation diagnostic and information solutions to inform optimized treatment decision-making, today announced 10,000 patients have been successfully enrolled in the FLEX Registry. Agendia’s unique FLEX Registry […]

ESR1 Mutations Provide Window Into Breast Cancer Metastasis

Via Peters

Present in approximately two-thirds of estrogen receptor-positive breast cancers, the role of ESR1 mutations in disease metastasis is poorly defined. Present in approximately two-thirds of estrogen receptor (ER)-positive breast cancers, the role of ESR1 mutations in disease metastasis is poorly defined.1 “It is an important research area because it is […]

Kerry O’Riordan McAdam, inspirational breast-cancer fund-raiser, business professional, and fitness enthusiast, has died at 31

Via Peters

Kerry O’Riordan McAdam, 31, of Philadelphia’s Fairmount neighborhood, a dynamic and inspirational fund-raiser for the fight against breast cancer, business professional, and lifelong fitness enthusiast, died Tuesday, April 26, of metastatic breast cancer at home. Ms. McAdam was diagnosed with metastatic breast cancer, also known as stage IV, in February […]

Global Breast Cancer Treatment Drugs Market Report, Growth Insight, Deep Research & Segment Analysis

Via Peters

Global “Breast Cancer Treatment Drugs Market” Reports 2022 provide key industry studies for Breast Cancer Treatment Drugs manufacturers with specific statistics, significance, definition, SWOT analysis, expert opinion and the latest developments in the world. The research report also covers market size, price, sales, revenue, market shares, gross margin, growth rate […]

Evidence for Practice and Research Recommendations

Via Peters

This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology. ABSTRACT Cancer-related fatigue (CRF) is one of the most common symptoms across the cancer continuum and is often underreported and undertreated. Defined as a distressing, persistent, subjective sense of tiredness or […]